EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics of Prostate Cancer Lesions on Dual Time-Point PET/CT: A Predictive Factor for Response to PSMA Radioligand Therapy?

Alexander Weissensee iD, Alan Daniel Sidandy, Clemens Mingels, Nasir Gözlügöl, Radi Saiyed Alsheikh, Mohamed Shelan, Federico Caobelli, Robert Seifert, Axel Rominger, Ali Afshar-Oromieh

Nuklearmedizin - NuclearMedicine · 12.11.2026

DOI: 10.1055/a-2981-3134 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, online erschienen am 12.11.2026. Verfasst von Alexander Weissensee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Inselspital University Hospital Bern, Department of Nuclear Medicine, Switzerland, Bern. Die Arbeit nennt 41 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PC) lesions usually show increasing uptake of prostate-specific membrane antigen (PSMA) ligands over time. We investigated whether the intensity changes of PSMA-ligand uptake on dual-time-point positron emission tomography/computed tomography (PET/CT) can predict the response to [177Lu]Lu-PSMA radioligand therapy (PSMA-RLT). Nineteen patients who underwent dual-time-point [18F]PSMA-1007 PET/CT before PSMA-RLT were retrospectively analysed. Standardised uptake values were measured for local prostate cancer lesions and lymph node, bone, and organ metastases. These groups were compared for maximum standardised uptake value (SUVmax) differences between standard and late scans. Using Firth’s bias-reduced logistic regression, we assessed whether change in SUVmax between standard and late scans (ΔSUVmax) correlates with long-term biochemical response to PSMA-RLT. We analysed 355 PC lesions (14 local tumours, 171 bone, 132 lymph node, and 38 organ metastases). Across all lesions, the median SUVmax in late scans was 15.2% higher than that in standard scans (p

Autor:innen und Institutionen

  • Inselspital University Hospital Bern, Department of Nuclear Medicine, Switzerland, Bern.
  • Luzerner Kantonsspital, Department of Nuclear Medicine and Radiology, Switzerland, Lucerne.
  • Hannover Medical School, Department of Nuclear Medicine, Germany, Hannover.
  • St. Claraspital, Department of Radiology and Nuclear Medicine, Switzerland, Basel.
  • Inselspital University Hospital Bern, Department of Radiation Oncology, Switzerland, Bern.

ORCID-Profile: Alexander Weissensee

Zitieren

APA

Weissensee, A., Sidandy, A. D., Mingels, C., Gözlügöl, N., Alsheikh, R. S., Shelan, M., Caobelli, F., Seifert, R., Rominger, A., & Afshar-Oromieh, A. (2026). Pharmacokinetics of Prostate Cancer Lesions on Dual Time-Point PET/CT: A Predictive Factor for Response to PSMA Radioligand Therapy?. Nuklearmedizin - NuclearMedicine. https://doi.org/10.1055/a-2981-3134

Vancouver

Weissensee A, Sidandy AD, Mingels C, Gözlügöl N, Alsheikh RS, Shelan M, et al. Pharmacokinetics of Prostate Cancer Lesions on Dual Time-Point PET/CT: A Predictive Factor for Response to PSMA Radioligand Therapy?. Nuklearmedizin - NuclearMedicine. 2026. doi:10.1055/a-2981-3134

BibTeX
@article{Weissensee2026,
  author = {Weissensee, Alexander and Sidandy, Alan Daniel and Mingels, Clemens and Gözlügöl, Nasir and Alsheikh, Radi Saiyed and Shelan, Mohamed and Caobelli, Federico and Seifert, Robert and Rominger, Axel and Afshar-Oromieh, Ali},
  title = {Pharmacokinetics of Prostate Cancer Lesions on Dual Time-Point PET/CT: A Predictive Factor for Response to PSMA Radioligand Therapy?},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2026},
  doi = {10.1055/a-2981-3134}
}
Kostenlos starten →